Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer

Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer

Abstract Immune checkpoint inhibitors (ICIs) are reportedly effective against many kinds of neoplasm, but may be responsible for several kinds of immune‐related adverse events (irAEs). Among these irAEs, the incidence of myelosuppression due to ICIs is relatively low. Corticosteroids are needed to c...

Full description

Bibliographic Details
Main Authors: Yuriko Ueki, Manabu Suzuki, Yuriko Horikawa, Hiromu Watanabe, Yoh Yamaguchi, Chie Morita, Akinari Tsukada, Hiroshi Takumida, Yusaku Kusaba, Takashi Katsuno, Yoshie Tsujimoto, Keita Sakamoto, Masao Hashimoto, Junko Terada, Satoru Ishii, Jin Takasaki, Go Naka, Motoyasu Iikura, Shinyu Izumi, Yuichiro Takeda, Masayuki Hojo, Haruhito Sugiyama
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Thoracic Cancer
Subjects:
Immune checkpoint inhibitor
immune‐related adverse event (irAE)
pancytopenia
PD‐L1
squamous cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.13582

Internet

https://doi.org/10.1111/1759-7714.13582

Similar Items